[Left ventricular hypertrophy and end-stage renal failure of unknown etiology: Fabry disease?]. 2012

A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000795 Fabry Disease An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders. Anderson-Fabry Disease,Angiokeratoma Corporis Diffusum,Angiokeratoma Diffuse,Angiokeratoma, Diffuse,Ceramide Trihexosidase Deficiency,Fabry's Disease,GLA Deficiency,Hereditary Dystopic Lipidosis,alpha-Galactosidase A Deficiency,alpha-Galactosidase A Deficiency Disease,Anderson Fabry Disease,Deficiency, Ceramide Trihexosidase,Deficiency, GLA,Deficiency, alpha-Galactosidase A,Diffuse Angiokeratoma,Lipidosis, Hereditary Dystopic,alpha Galactosidase A Deficiency,alpha Galactosidase A Deficiency Disease
D017379 Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality. Left Ventricular Hypertrophy,Ventricular Hypertrophy, Left,Hypertrophies, Left Ventricular,Left Ventricular Hypertrophies,Ventricular Hypertrophies, Left

Related Publications

A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
January 1988, Nephron,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
July 2016, Iranian journal of kidney diseases,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
January 1993, Journal of Tongji Medical University = Tong ji yi ke da xue xue bao,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
August 1987, The American journal of cardiology,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
August 1989, Kidney international,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
January 1987, American journal of nephrology,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
October 2016, Journal of biomedical research,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
February 2004, The International journal of artificial organs,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
December 1992, The American journal of cardiology,
A Arévalo-Gómez, and S Rivera-García, and A López-Muñiz, and R Barriales-Villa
November 2014, Current opinion in nephrology and hypertension,
Copied contents to your clipboard!